<DOC>
	<DOC>NCT00156910</DOC>
	<brief_summary>This is a 60 week study including a double-blind phase followed by an open-label extension phase.</brief_summary>
	<brief_title>A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients With Frequent Headaches</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Botulinum Toxins, Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Frequent migraine (&gt;=15 headache days per month) &gt;=4 distinct headache episodes lasting &gt;=4 hours &gt;=50% of baseline headache days migraine/probable migraine days Previous use of botulinum toxin of any serotype or immunization to any botulinum toxin serotype Any medical condition that puts the patient at increased risk with exposure to BOTOX Diagnosis of complicated migraine, chronic tensiontype headache, hypnic headache, hemicrania continua, new daily persistent headache Use of prophylactic headache medication within 28 days prior to week 4 Unremitting headache lasting continuously throughout the 4week baseline period Known or suspected Temporomandibular Disorders (TMD) Diagnosis of fibromyalgia Beck depression inventory score &gt;24 at week4 Psychiatric problems that may have interfered with study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>